Early complete response a validated surrogate marker in extranodal marginal zone lymphoma systemic therapy

•Surrogate markers provide early decision-making end points for regulatory agencies; they serve as substitutes for long-term end points.•In extranodal MZL, CR24 mediates 90% and TTCR24 captures 95% of treatment effect on 8-year PFS, which makes them valid early indicators.